High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma

Bone Marrow Transplantation

Volumn 34, Issue 7, 2004, Pages 581-587

  Wang, E H ^a   Chen, Y A ^a   Corringham, S ^a   Bashey, A ^a   Holman, P ^a   Ball, E D ^a   Carrier, E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autologous; Chemotherapy; Lymphoma

Indexed keywords

ACICLOVIR; CARMUSTINE; CEFTAZIDIME; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; VANCOMYCIN;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CANCER GRADING; CANCER SURVIVAL; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DIARRHEA; DRUG ERUPTION; DRUG MEGADOSE; DRUG RESPONSE; EYE TOXICITY; FEBRILE NEUTROPENIA; FEMALE; HODGKIN DISEASE; HUMAN; INFUSION; INFUSION REACTION; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MYCOSIS; NEPHROTOXICITY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SEPTICEMIA; SIDE EFFECT; STATISTICAL SIGNIFICANCE; VIRUS INFECTION;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LENGTH OF STAY; LYMPHOMA; MALE; MELPHALAN; MIDDLE AGED; PODOPHYLLOTOXIN; PROGNOSIS; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 5044251361     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704637     Document Type: Article

References (20)

1. Alessandrino EP, Bernasconi P, Colombo A et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant 2000; 25: 309-313.
2. Patti C, Majolino I, Scime R et al. High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas. Eur J Haematol 1993; 51: 18-24.
3. Reece DE, Barnett MJ, Conners JM et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991; 9: 1871-1879.
4. Reece DE, Nevill TJ, Sayegh A et al. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease. Bone Marrow Transplant 1999; 23: 1131-1138.
5. Schmitz N, Glass B, Dreger P et al. High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease. Ann Hematol 1993; 66: 251.
6. Wheeler C, Antin JH, Churchill WH et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and Non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol 1990; 8: 648-656.
7. Argiris A, Seropian S, Cooper DL. High-dose BEAM chemotherapy with autologous peripheral blood-progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. Ann Oncol 2000; 11: 665-672.
8. Fleming DR, Wolff SN, Fay JW et al. Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow Transplant Group. Leuk Lymphoma 1999; 35: 91-98.
9. Mills W, Chopra R, McMillan A et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 588-595.
10. Bierman PJ, Anderson JR, Freeman MB et al. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy. Ann Oncol 1996; 7: 151-156.
11. Chopra R, McMillan AK, Linch DC et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993; 81: 1137-1145.
12. Lindley C, Finley RS, Shord SS. Adverse effects of chemotherapy. In: Koda-Kimble MA, Young LY (eds.). Applied Therapeutics: The Clinical Use of Drugs, 7th edn. Lippincott Williams & Wilkins: Philadelphia, 2001; pp 87-1-87-41.
13. Jantunen E, Kuittinen T, Nousiainen T. BEAC or BEAM for high-dose therapy in patients with Non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy. Leuk Lymphoma 2003; 44: 1151-1158.
14. Lindley C, Shord SS, Finley RS. Neoplastic disorders and their treatment: general principles. In: Koda-Kimble MA, Young LY (eds). Applied Therapeutics: The Clinical Use of Drugs, 7th edn. Lippincott Williams & Wilkins: Philadelphia, 2001; pp 86-1-86-33.
15. Spinolo JA, Jagannath S, Dicke KA et al. High-dose combination chemotherapy with cyclophosphamide, carmustine, etoposide, and autologous bone marrow transplantation in 60 patients with relapsed Hodgkin's disease: The M.D. Anderson experience. Recent Results Cancer Res 1989; 117: 233-238.
16. Caballero MD, Rubio V, Rifon J et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997; 20: 451-458.
17. Salar A, Sierra J, Gandarillas M et al. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens. Bone Marrow Transplant 2001; 27: 405-412.
18. Arranz R, Tomas JF, Gil-Fernandez JJ et al. Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease (HD): comparative results with two CBV regimens and importance of disease status at transplant. Bone Marrow Transplant 1998; 21: 779-786.
19. Bierman PJ, Bagin RG, Jagannath S et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients. Ann Oncol 1993; 4: 767-773.
20. Finley RS, Treish IM, Lindley CM. Hematologic malignancies. In: Koda-Kimble MA, Young LY (eds.). Applied Therapeutics: The Clinical Use of Drugs, 7th edn. Lippincott Williams & Wilkins: Philadelphia, 2001; pp 88-1-88-37.